UNSPSC 51287006: Glucosulfone

This classification denotes a sulfone anti-infective agent with the molecular formula C24H34N2O18S3.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6RLN7D44F, chemically known as sodium glucosulfone, injection but more generally known as glucosulfone, which bears US NIH Compound Identifier 3481. European Medicines Agency schedules Glucosulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07939MIG. The term GLUCOSULFONE is an International Non-Proprietary Name.

GLUCOSULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(O)C(NC1CCC(S(=O)(=O)C2CCC(NC(S(=O)(=O)O)C(O)C(O)C(O)C(O)CO)CC2)CC1)C(O)C(O)C(O)C(O)CO.

UNSPSC 51287006 Glucosulfone is a Commodity code that does not align with the recent state and local procurement activity tagged to it. The source shows no current solicitations or awards for glucosulfone itself. Instead, the two most recent opportunities tagged to this code involve pharmaceutical procurement for other products entirely: the Illinois Department of Public Health's August 2026 award to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through a piggyback MMCAP Infuse consortium contract, and Seminole County, Florida's June 2026 IFB for Naloxone and drug deactivation systems. Neither opportunity includes glucosulfone in its scope. The mismatch suggests either a cataloging error in the state or local procurement system or that glucosulfone is being procured under a different code when state and local governments do purchase it.

The two opportunities demonstrate activity among state health departments and county health or emergency-management offices, with geographic presence in Florida and Illinois. The Illinois award to Chartwell Rx LLC totaled $2,999,999.11 over a 12-month initial term with two optional renewal years and was competed through an Invitation for Bid under the MMCAP consortium. Seminole County's IFB (60459723LAS), due July 26, 2023, sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and included FEMA funding compliance requirements. Neither opportunity is directly relevant to glucosulfone procurement; business development professionals should verify whether this code is the correct target for glucosulfone supply or whether a different code better reflects current state and local buying patterns for this pharmaceutical.